Form 4: ORAMED CEO Acquires 109K Shares Post-PSU Vesting
Insider Transaction Report
Oramed Pharmaceuticals CEO Nadav Kidron acquired 109,000 common shares following the vesting of performance stock units tied to a specific stock price achievement.
Summary
- Nadav Kidron, President and CEO, and a Director of ORAMED PHARMACEUTICALS INC. (ORMP), reported an acquisition of common stock.
- On January 22, 2026, 109,000 performance stock units (PSUs) granted on December 31, 2025, vested.
- The vesting occurred because Oramed's common stock achieved a specified price per share.
- Upon vesting, Mr. Kidron received 109,000 shares of common stock for no consideration.
- Following this transaction, Mr. Kidron beneficially owns 3,355,238 shares of Oramed Pharmaceuticals common stock.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive event, as the vesting of performance-based equity suggests the company has met specific stock price targets, reflecting underlying operational or market success.
Positives
- The vesting of 109,000 performance stock units indicates that Oramed Pharmaceuticals' common stock achieved a specified price per share, signaling positive company performance.
- The acquisition of shares by the CEO aligns management's interests with those of shareholders.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance beyond the reported transaction.
Industry Context
StockSavvy.ai notes that insider transactions, particularly those involving performance-based equity vesting for a CEO, can be interpreted by the market as a signal of management's confidence in the company's future prospects and its ability to meet strategic targets.
Stakeholder Impact
- Shareholders: The vesting of performance-based equity for the CEO suggests the company has met specific stock price targets, which is generally positive for shareholder value.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Grant date of Performance Stock Units (PSUs) to Nadav Kidron. |
| 01/22/2026 | Vesting date of 109,000 Performance Stock Units and acquisition of common stock by Nadav Kidron. |
| 01/29/2026 | Date the Form 4 filing was signed by Nadav Kidron. |
Keywords
ORAMED PHARMACEUTICALS, ORMP, Nadav Kidron, Form 4, insider transaction, performance stock units, PSU vesting, equity compensation, stock acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.